Toyota Highlander Recall Issued Over Stall, Accident Risk

Toyota Recall

Nearly 40,000 Toyota Highlander vehicles have been recalled due to a programming error, which could result in a fuel shortage that leads to a sudden engine stall, increasing the risk of an auto accident if the vehicle is in motion.

The U.S. National Highway Traffic Safety Administration (NHTSA) announced a Toyota Highlander recall on March 27, following customer reports of the engines unexpectedly stalling due to a programming error in the engine fuel supply module.

The impacted vehicles are equipped with a start-stop feature, which shuts the engine down and restarts it while the vehicle is temporarily stopped. During these start-stop events, the Engine Control Unit (ECU) cuts off the fuel supply under certain driving conditions.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

According to Toyota, a software programming error may cause the ECU to fail to re-enable the fuel flow to the engine after a start-stop event, which could lead to stalling and an increased risk of crashing.

The recall includes approximately 38,810 model year 2020 Toyota Highlander vehicles  manufactured between June 24, 2019 and March 4, 2020. The impacted vehicles were manufactured by Toyota Motor Engineering & Manufacturing of Plano, Texas. They were distributed for sale throughout the U.S. to licensed dealers.

Toyota announced it will begin notifying owners by mailed notice, and will provide instructions on how to schedule a repair appointment at their local dealer, who will be instructed to reprogram the ECU free of charge.

Highlander customers are being warned to be cautious of warning lights illuminating on the dashboard, which may be indicating the engine is stalling.

Since no physical components are required, Toyota announced the recall repair campaign is expected to begin on April 24, 2020. Customers with additional questions or concerns may contact Toyota Customer Service at 1-888-270-9371 and reference the recall number 20TA06.

Written by: Russell Maas

Managing Editor & Senior Legal Journalist

Russell Maas is a paralegal and the Managing Editor of AboutLawsuits.com, where he has reported on mass tort litigation, medical recalls, and consumer safety issues since 2010. He brings legal experience from one of the nation’s leading personal injury law firms and oversees the site’s editorial strategy, including SEO and content development.

Image Credit: Image via <a href="http://www.shutterstock.com/gallery-365671p1.html?cr=00&pl=edit-00">FotograFFF</a> / <a href="http://www.shutterstock.com/editorial?cr=00&pl=edit-00">Shutterstock.com</a>



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A Florida jury has ordered Johnson & Johnson to pay $20 million to the family of a man who died of mesothelioma after using the company’s talc-based products for 50 years.
Sanofi indicates Dupixent sales are growing stronger as the medication gathers more indications for use worldwide, despite recent cancer concerns.
Researchers warn that sports-betting apps use reward-based design and constant engagement tactics that can fuel addiction among young adults—sparking a surge of lawsuits accusing major platforms of exploiting these vulnerabilities for profit.